Savara (SVRA) announced that it has completed submission of the BLA to the FDA for MOLBREEVI as a treatment for aPAP. “Submission of the BLA ...

LANGHORNE, PA — Savara Inc. (Nasdaq: SVRA) has announced the completion of its Biologics License Application (BLA) submission ...

LANGHORNE, PA — Savara Inc. (Nasdaq: SVRA) has announced its financial results for the fourth quarter and fiscal year 2024, ...

Matt Pauls, Chair and CEO of Savara, expressed optimism about the data supporting MOLBREEVI’s efficacy in improving pulmonary gas exchange and clinical symptoms of aPAP. Savara has requested a ...

Matt Pauls, Chair and CEO of Savara, expressed optimism about the data supporting MOLBREEVI’s efficacy in improving pulmonary gas exchange and clinical symptoms of aPAP. Savara has requested a ...

Savara Inc. (NASDAQ:SVRA), a biopharmaceutical company focused on developing novel therapies for rare respiratory diseases, is approaching a critical juncture in its journey to bring its lead ...

As the company completes its rolling Biologics License Application (BLA) submission for Molbreevi, investors and analysts are closely watching the potential first-in-class treatment for autoimmune ...

Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that it has entered into a loan and security agreement with ...

If Priority Review is granted by the FDA, MOLBREEVI could potentially be approved by the end of the year. The Company remains on track to file the Marketing Authorization Application for MOLBREEVI ...

Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the fourth quarter and full year ending ...

Completed Submission of the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI * as a Treatment for Autoimmune Pulmonary Alveolar Proteinosis (aPAP ...